Dry Eye Disease

NEW ORLEANS — Research presented at Academy ’23 demonstrated that perfluorohexyloctane, which is indicated for dry eye disease, reduces corneal staining up to four times more than saline.

NEW ORLEANS — Twice-daily Cequa improved symptoms of dry eye disease and decreased corneal staining in patients who were still symptomatic or exhibiting signs of disease on current therapy, according to a poster presented at Academy ’23.

Ophthalmologists must pay attention to the state of the ocular surface to try to avoid unhappy patients after cataract surgery, according to a presentation from Real World Ophthalmology.

Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.

Sigh. I really thought we would have some new stuff to chat about now that it is September 2023. I mean, you know, besides Brent Saunders.

OKYO Pharma has completed patient enrollment for the randomized portion of its phase 2 clinical trial of OK-101, a topical treatment for dry eye disease, the company announced in a press release.

Bausch + Lomb has announced the U.S. commercial launch of Miebo, a perfluorohexyloctane ophthalmic solution designed to treat signs and symptoms of dry eye disease by directly targeting tear evaporation.

The American Optometric Association has announced the launch of Blink Land, its single-player mobile game that aims to teach players about the relationship between eye health and screen time.

Over the past month, Healio has reported on a variety of tech news in eye care, including embedded hearing technology in prescription eyeglasses and the accuracy of artificial intelligence when screening for diabetic retinopathy.

Talking about the importance of a healthy ocular surface is part of my routine education for glaucoma patients.